665254

research-article2016

TAG0010.1177/1756283X16665254Therapeutic Advances in GastroenterologyA Kohli, A Alshati

Therapeutic Advances in Gastroenterology

Review

Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease

Ther Adv Gastroenterol 2016, Vol. 9(6) 887­–897 DOI: 10.1177/ 1756283X16665254 © The Author(s), 2016. Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav

Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch and Robert G. Gish

Abstract:  All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs for treatment of CKD patients. The National Library of Medicine through PubMed was searched for studies evaluating the efficacy of DAAs for the treatment of patients with CKD stages 4 or 5, as defined by the Kidney Disease Outcomes Quality Initiative guidelines [i.e. glomerular filtration rate (GFR) 15–29 ml/min per 1.73 m2 and GFR